First‐in‐human study of HDM1002 , a GLP ‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16610 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Junliang Pu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Center, Bishan Hospital of Chongqing, Bishan Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Aims
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single oral doses of HDM1002 in healthy adult participants. Materials and Methods This was a first‐in‐human, randomized, double‐blind, placebo‐controlled, 2‐part study. Healthy participants aged 18 to 55 years with a body mass index (BMI) of 19.0 ~ 32.0 kg/m 2 were eligible. In the single ascending dose (SAD) part, eligible participants were randomized (8:2) to receive a single oral escalating dose of HDM1002 (10–600 mg) or placebo. In the food effect (FE) part, participants were randomized (7:7) to receive HDM1002 (200 mg) in the fasted and fed states with a two‐period, crossover design.
Results
A total of 79 participants enrolled and completed the study. The most common adverse events (AEs) were nausea, diarrhoea, vomiting and decreased appetite, which increased in a dose‐dependent manner. No serious AEs were reported. C max and AUC appeared to be dose‐proportional from 10 to 600 mg by a power model. The geometric mean t 1/2 z ranged from 4.99 to 7.10 h. C max and AUC of HDM1002 were similar under fed and fasted conditions. HDM1002 significantly lowered postprandial glucose in a dose‐dependent manner and maintained the glucose‐lowering effect at both 6 and 12 h at 100–600 mg doses.
Conclusions
HDM1002 was safe and well tolerated at 10–600 mg. HDM1002 showed linear pharmacokinetics, and a standardized high‐fat meal did not impact systemic exposure. These results provide preliminary evidence supporting further clinical development of HDM1002 in individuals with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Center, Bishan Hospital of Chongqing, Bishan Hospital of Chongqing Medical University, Chongqing, China.
- Huadong Global Innovative Development Center, Hangzhou Zhongmei Huadong Pharmaceutical Company, Hangzhou, Zhejiang, China.
ORCID-Profile: Junliang Pu, Yurui Huang, Lei Wan, Mingxue Zhu, Chengyong Tang
Förderung
- Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd
Zitieren
APA
Pu, J., Huang, Y., Wan, L., Zhu, M., Wei, H., Gao, H., Zhong, L., Tang, C., & Xu, J. (2025). First‐in‐human study of HDM1002 , a GLP ‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16610
Vancouver
Pu J, Huang Y, Wan L, Zhu M, Wei H, Gao H, et al. First‐in‐human study of HDM1002 , a GLP ‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16610
BibTeX
@article{Pu2025,
author = {Pu, Junliang and Huang, Yurui and Wan, Lei and Zhu, Mingxue and Wei, Huili and Gao, Hong and Zhong, Liping and Tang, Chengyong and Xu, Junfang},
title = {First‐in‐human study of HDM1002 , a GLP ‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16610}
}
EUVIMED